Bristol-Myers Squibb on Wednesday said it would present 23 abstracts related to Orencia (abatacept), including new data on the role of biomarkers and MRI in RA patient identification and treatment, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.
The company said it would also share first-in-human data from BMS-986165, an investigational TYK2 inhibitor, at the conference in progress from 14-17 June.
The abstracts from Bristol-Myers Squibb accepted for EULAR 2017 include three practice-informing analyses pertaining to Orencia treatment responses in patients with highly active, progressive rheumatoid arthritis (RA), who traditionally have a poor prognosis.
“The research Bristol-Myers Squibb is presenting at EULAR 2017 shows our commitment to advancing scientific understanding of how biomarkers and tools, such as MRI, can be used to guide patient selection and treatment in highly active, progressive rheumatoid arthritis,” said Brian J. Gavin, Vice President, Orencia Development Lead at Bristol-Myers Squibb.
He said that the research also yields critical insights into the role of modulating the body’s immune system in rheumatoid arthritis and potentially other autoimmune conditions.